Bioequivalence Study of Ibuprofen 400 mg/10 mL Oral Suspension vs. MOMENTACT 400 mg Film-coated Tablet

NCT ID: NCT02902302

Last Updated: 2016-09-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-05-31
• Study Completion Date: 2016-07-31

Brief Summary

The main objective of the study is to evaluate the bioequivalence of a new formulation of ibuprofen 400 mg/10 mL oral suspension vs. the marketed reference product MOMENTACT 400 mg film-coated tablet, when administered under fasting conditions as single oral dose to healthy male and female volunteers, in two consecutive study periods.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

Ibuprofen 400 mg/10 mL oral suspension

Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.

Group Type: EXPERIMENTAL

Ibuprofen 400 mg/10 mL oral suspension

Intervention Type: DRUG

MOMENT 400 mg coated tablet

Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.

Group Type: ACTIVE_COMPARATOR

MOMENT 400 mg coated tablet

Intervention Type: DRUG

Interventions

Ibuprofen 400 mg/10 mL oral suspension

Intervention Type: DRUG

MOMENT 400 mg coated tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Informed consent: signed written informed consent before inclusion in the study

2. Sex and Age: males/females, 18-55 years old inclusive

3. Body mass index (BMI): 18.5-30 kg/m2 inclusive

4. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the sitting position

5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study

6. Contraception and fertility (females only): females of child-bearing potential must be using at least one of the following reliable methods of contraception:

1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit

2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit

3. A male sexual partner who agrees to use a male condom with spermicide

4. A sterile sexual partner Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, pregnancy test result must be negative at screening and day -1.

Exclusion Criteria

1. Electrocardiogram (12-leads, supine position): clinically significant abnormalities

2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study

3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness

4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients or related drugs, namely non-steroidal anti-inflammatory agents (NSAIDs); history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study

5. Diseases: history of significant renal, hepatic, gastrointestinal (in particular gastroduodenal ulcer and bleeding), cardiovascular, respiratory (in particular asthma), skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study

6. Medications: medications, including over the counter medications (in particular ibuprofen) and herbal products for 2 weeks before the start of the study. Hormonal contraceptives for females will be allowed

7. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study

8. Blood donation: blood donations for 3 months before this study

9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to USDA Dietary Guidelines 2015-2020], caffeine (>5 cups coffee/tea/day) or tobacco abuse (≥10 cigarettes/day)

10. Drug test: positive result at the drug test at screening or day-1

11. Alcohol test: positive alcohol breath test at day -1

12. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians

13. Pregnancy (females only): positive or missing pregnancy test at screening or day -1, pregnant or lactating woman

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cross Research S.A.

INDUSTRY

Sponsor Role: collaborator

Aziende Chimiche Riunite Angelini Francesco S.p.A

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Milko Radicioni, MD

Role: PRINCIPAL_INVESTIGATOR

Cross Research S.A.

Locations

CROSS Research S.A., Phase I Unit

Arzo, Switzerland, Switzerland

Countries

Switzerland

Other Identifiers

CRO-PK-15-307

Identifier Type: OTHER

Identifier Source: secondary_id

070(Q)HO15412

Identifier Type: -

Identifier Source: org_study_id